

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

### 石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY

On 30 May 2023, CSPC Pharmaceutical Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) granted a total of 3,000,000 awards of restricted shares (the “**Awarded Shares**”) pursuant to the restricted share award scheme adopted on 20 August 2018 (the “**Scheme**”) to 6 employees of the Group (collectively, the “**Grantees**”) who are not directors, chief executives or substantial shareholders of the Company or an associate of any of them (as defined under the Listing Rules), subject to the acceptance by the Grantees (the “**Grant**”).

Details of the Grant are set out as follows:

Date of grant	:	30 May 2023
Number of Awarded Shares	:	3,000,000 Awarded Shares, representing the same number of shares in the Company (“ <b>Shares</b> ”) and approximately 0.025% of the issued Shares as at the date of this announcement.
Purchase price of the Awarded Shares	:	Nil cost per Awarded Share
Closing price of the Shares as at the date of Grant	:	HK\$6.85 per Share
Vesting date	:	Subject to acceptance by each of the Grantees and the clawback/lapse mechanisms as set out below, the Awarded Shares shall vest in the relevant Grantees on 10 July 2023.

- Performance targets : There are no performance targets attached to the Awarded Shares granted to the Grantees.
- Clawback/Lapse mechanism : Where a Grantee (i) ceases to be an employee of the Company or its subsidiaries, (ii) becomes bankrupt or fails to pay his or her debts within a reasonable time after they become due or makes any arrangement or composition with his/her creditors generally, (iii) becomes convicted for any criminal offence, or (iv) is charged, convicted or held liable for any offence under securities laws in Hong Kong or other applicable laws or regulations, any unvested Awarded Shares granted shall automatically lapse.

The above Grant would not result in the Shares issued and to be issued in respect of all options and awards granted to each Grantee in the 12-month period up to and including the date of such Grant in aggregate to be over 1% of the Shares in issue.

The Awarded Shares have been purchased by BOCI-Prudential Trustee Limited (“**Trustee**”) through on-market transactions and are currently held by the Trustee in accordance with the rules of the Scheme and the trust deed entered into between the Company and the Trustee, and the Trustee shall transfer such Awarded Shares to the relevant Grantees according to the relevant vesting date.

## **REASONS FOR AND BENEFITS OF THE GRANT**

The grant of Awarded Shares is to recognize the Grantees for their contribution to the Group, to encourage and retain such individuals to strive for the future development of the Group by providing them with the opportunity to own equity interests in the Company.

## **LISTING RULES IMPLICATIONS**

After the grant of Awarded Shares pursuant to this announcement, 117,304,368 Awarded Shares will be available for future grants under the Scheme. The Scheme was adopted before the effective date of the new Chapter 17 of the Listing Rules (effective on 1 January 2023). The Company will comply with the new Chapter 17 of the Listing Rules in accordance with the transitional arrangements provided for the existing share schemes of the Group.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 30 May 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*